LSP TEAM » Jörg Neermann


Jörg Neermann, PhD, joined LSP in 2007 as Partner.  Jörg’s prime focus and responsibility within LSP is to invest in unlisted securities. Prior to joining LSP, Jörg was the Managing Director of Deutsche Bank’s DVC, where he ran its healthcare investment franchise. Previously, he worked at Atlas Ventures in Germany where he also invested in the healthcare sector. Jörg brings a strong scientific background and hands-on finance and investment expertise to the LSP team. He has been appointed a Director at a large number of companies, all of which he has helped with his scientific expertise, biotechnology experience and global networks. Among others, Jörg is currently a Director at Probiodrug, a German biotech company that went public on Euronext Amsterdam in 2014 and is active in the development of novel, disease modifying therapeutics against Alzheimer’s disease. Jörg holds a Master’s degree and a PhD in Biotechnology from the Technical University in Braunschweig and MIT in Cambridge, US. He also studied economics at Harvard Business School, US. Jörg lives in Munich with his wife and two children.
 
To contact Jörg directly, email warreznaa@yfcip.pbz or call +49 (0) 89 330 666-0.
 

LSP TEAM » Jörg Neermann


Jörg Neermann, PhD, joined LSP in 2007 as Partner.  Jörg’s prime focus and responsibility within LSP is to invest in unlisted securities. Prior to joining LSP, Jörg was the Managing Director of Deutsche Bank’s DVC, where he ran its healthcare investment franchise. Previously, he worked at Atlas Ventures in Germany where he also invested in the healthcare sector. Jörg brings a strong scientific background and hands-on finance and investment expertise to the LSP team. He has been appointed a Director at a large number of companies, all of which he has helped with his scientific expertise, biotechnology experience and global networks. Among others, Jörg is currently a Director at Probiodrug, a German biotech company that went public on Euronext Amsterdam in 2014 and is active in the development of novel, disease modifying therapeutics against Alzheimer’s disease. Jörg holds a Master’s degree and a PhD in Biotechnology from the Technical University in Braunschweig and MIT in Cambridge, US. He also studied economics at Harvard Business School, US. Jörg lives in Munich with his wife and two children.
 
To contact Jörg directly, email warreznaa@yfcip.pbz or call +49 (0) 89 330 666-0.